Asset profile

Atezolizumab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved — Non-Small Cell Lung Cancer

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

How the evidence outlook works ↗

Featured trials

Research

Unlock featured-trial analysis

Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.

Upcoming events

(35 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (15)

August 2026 (2)

Phase 2Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Breast Carcinoma …Active not recruiting

Est. primary completion 2026-08-31 · NCT02849496 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Triple Negative Breast CancerActive not recruiting

Est. primary completion 2026-08-31 · NCT05498896 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2026 (1)

Phase 2Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8Active not recruiting

Est. primary completion 2026-09-01 · NCT04310020 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2026 (1)

Phase 2/3Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2026-10-31 · NCT03178552 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2026 (2)

Phase 2Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2026-11 · NCT05798663 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2026-11-30 · NCT04302025 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (9)

Phase 1/2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2026-12 · NCT04691817 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors, Ovarian Cancer, Pancreatic Adenocarcinoma …Recruiting

Est. primary completion 2026-12 · NCT05000294 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2026-12 · NCT03915678 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HER2-positive Breast CancerActive not recruiting

Est. primary completion 2026-12 · NCT03125928 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2026-12-01 · NCT05825625 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Triple Negative Breast CancerRecruiting

Est. primary completion 2026-12-15 · NCT06690840 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Invasive Breast CancerActive not recruiting

Est. primary completion 2026-12-15 · NCT03595592 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNARecruiting

Est. primary completion 2026-12-30 · NCT04434040 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8 …Active not recruiting

Est. primary completion 2026-12-31 · NCT05340309 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (9)

January 2027 (2)

Phase 1/2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-01-01 · NCT04467723 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 …Recruiting

Est. primary completion 2027-01-01 · NCT06731270 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2027 (1)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-02 · NCT06463665 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2027 (1)

Phase 2Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2027-05 · NCT03896074 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2027 (2)

Phase 3Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-06-01 · NCT05317858 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related ChangesActive not recruiting

Est. primary completion 2027-06-30 · NCT02935361 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2027 (1)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-09-01 · NCT04253964 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2027 (1)

Phase 2Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Gynecologic Cancer, Sarcoma, Unknown Primary Tumors …Recruiting

Est. primary completion 2027-10 · NCT04273061 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (1)

Phase 2Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory CarcinomaActive not recruiting

Est. primary completion 2027-12-31 · NCT03202316 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (2)

January 2028 (1)

Phase 2Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2028-01-31 · NCT02525757 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2028 (1)

Phase 3Breast CancerActive not recruiting

Est. primary completion 2028-08-31 · NCT04873362 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (3)

April 2029 (1)

Phase 3Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8Recruiting

Est. primary completion 2029-04-30 · NCT06632327 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2029 (1)

Phase 1/2Inoperable, Locally Advanced or Metastatic, ER-positive Breast CancerRecruiting

Est. primary completion 2029-05-30 · NCT04802759 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2029 (1)

Phase 2Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2029-08-31 · NCT03228667 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (3)

March 2030 (1)

Phase 2Early-stage Breast CancerRecruiting

Est. primary completion 2030-03 · NCT05332561 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2030 (1)

Phase 1/2Metastatic Breast CancerRecruiting

Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2030 (1)

Phase 2Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma …Not yet recruiting

Est. primary completion 2030-11-01 · NCT07322341 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2032 (1)

September 2032 (1)

Phase 3Lung Non-Small Cell CarcinomaRecruiting

Est. primary completion 2032-09-30 · NCT07388524 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2035 (1)

May 2035 (1)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2035-05-02 · NCT07153445 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2040 (1)

February 2040 (1)

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2040-02-28 · NCT07770100 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.